Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group-Reference-Cited by-同舟云学术

Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group

Published:2011-03-18 Issue:1 Volume:26 Page:48-53
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:

Author:

Pflugfelder A.,Welter A.-K.,Leiter U.,Weide B.,Held L.,Eigentler T.K.,Dirschka T.,Stockfleth E.,Nashan D.,Garbe C.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-3083.2011.04005.x/fullpdf

Reference24 articles.

1. Epidemiology of actinic keratoses and squamous cell carcinoma;Salasche;J Am Acad Dermatol,2000

2. Epidemiology of solar keratoses;Frost;Br J Dermatol,1994

3. Clinical presentation of actinic keratoses and squamous cell carcinoma;Moy;J Am Acad Dermatol,2000

4. Solar (actinic) keratosis is squamous cell carcinoma;Ackerman;Br J Dermatol,2006

5. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis;Gallo;Neoplasia,2001

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European consensus‐based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV‐induced dysplasia and field cancerization on behalf of European Association of Dermato‐Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes);Journal of the European Academy of Dermatology and Venereology;2024-03-07

2. Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm²: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis;Clinical Pharmacology in Drug Development;2024-01-07

3. Poor Adherence to Self-Applied Topical Drug Treatment Is a Common Source of Low Lesion Clearance in Patients with Actinic Keratosis—A Cross-Sectional Study;Journal of Clinical Medicine;2023-06-01

4. Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland;PharmacoEconomics - Open;2023-04-03

5. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27